AP4 promotes HCC cell proliferation, migration and invasion and reduces chemotherapy sensitivity via LAPTM4B by activating the phosphoinositide 3‐kinase (PI3K)/protein kinase B (AKT) signalling pathway and caspase‐dependent pathway. This evidence concerns the gene AKT1 and hepatocellular carcinoma.